Home The Word Brain My Amedeo FAQ Privacy About


Amedeo Chinese

For Medical Students & Physicians

A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever.

Download the free PDF: Amedeo Chinese PDF

  Leukemia

  Free Subscription


28.09.2026

2 Blood
1 BMC Cancer
1 Cancer
1 Eur J Haematol
2 Int J Hematol
1 J Natl Cancer Inst
2 Leuk Res
3 Leukemia
2 PLoS One


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Blood

  1. LUSKIN MR, Keating JH, Frost BF, Jaeckle SL, et al
    Venetoclax plus Inotuzumab Ozogamicin for Relapsed and Refractory Acute Lymphoblastic Leukemia.
    Blood. 2026 Sep 25:blood.2026035238. doi: 10.1182/blood.2026035238.
    PubMed         Abstract available

  2. AL AMRI R, Bailey N
    NPM1-mutated myeloid neoplasm presenting as chronic eosinophilic leukemia.
    Blood. 2026;148:1754.
    PubMed        


    BMC Cancer

  3. ZHANG C, Luo Q, Wu S, Xu L, et al
    Human single domain antibody-based CAR-T cells targeting BAFF-R demonstrate promising preclinical activity in B-cell malignancies.
    BMC Cancer. 2026;26:1125.
    PubMed         Abstract available


    Cancer

  4. MOYER P, Leguay T, Jullien M, Huguet F, et al
    Outcome after first relapse post-immunochemotherapy in older adults with Philadelphia-negative B-cell acute lymphoblastic leukemia: A GRAALL study.
    Cancer. 2026;132:e70621.
    PubMed         Abstract available


    Eur J Haematol

  5. TATAR D, Yilmaz E, Ozer NK
    Comment on Sakthivel Et al., "Central Venous Access Device Complications in Children With Leukemia: A Systematic Review and Meta-Analysis".
    Eur J Haematol. 2026 Sep 25. doi: 10.1111/ejh.70325.
    PubMed        


    Int J Hematol

  6. WERNICKE GJ, Enrico AI, Cattaneo M, Bendek Del Prete GE, et al
    Allogeneic transplantation outcomes in chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
    Int J Hematol. 2026 Sep 23. doi: 10.1007/s12185-026-04281.
    PubMed         Abstract available

  7. NAJIMA Y
    Strategies to prevent post-transplant relapse in acute myeloid leukemia and myelodysplastic syndromes.
    Int J Hematol. 2026 Sep 19. doi: 10.1007/s12185-026-04282.
    PubMed         Abstract available


    J Natl Cancer Inst

  8. ZHANG GQ, Ma C, Yang VB, Shi Q, et al
    Physical activity and molecular residual disease in stage III colon cancer: Findings from Cancer and Leukemia Group B (Alliance)/SWOG 80702.
    J Natl Cancer Inst. 2026 Sep 24:djag342. doi: 10.1093.
    PubMed         Abstract available


    Leuk Res

  9. DUTTA R, Schumann C, Cheung E, Zhang TY, et al
    Cladribine and low-dose cytarabine as first salvage after hypomethylating agent and venetoclax in acute myeloid leukemia.
    Leuk Res. 2026;171:108322.
    PubMed         Abstract available

  10. LIPTON JH
    Chronic myeloid leukemia is not a familial disease...or maybe it is?
    Leuk Res. 2026;170:108324.
    PubMed        


    Leukemia

  11. DROBNA-SLEDZINSKA M, Buratin A, Roncaglia E, Caregari A, et al
    Systematic profiling of AGO2-associated circRNAs and functional investigation reveal circN4BP2L2 as a survival-promoting regulator in T-ALL.
    Leukemia. 2026;40:2223-2235.
    PubMed         Abstract available

  12. KIM AS, Long T, Oldridge DA, Jennings LJ, et al
    Improved inter-lab precision after CML international scale adoption: a 15-year history of BCR::ABL1 proficiency testing.
    Leukemia. 2026;40:2236-2243.
    PubMed         Abstract available

  13. HEIBLIG M, Gross Z, Belhabri A, Tauveron-Jalenques U, et al
    Prognostic impact of measurable residual disease in AML patients treated frontline with azacitidine and venetoclax: results from the French VENAURA registry.
    Leukemia. 2026;40:2191-2201.
    PubMed         Abstract available


    PLoS One

  14. ZATARAH R, Albdour T, Assad A, Budair R, et al
    Bacterial profile and antibiotic susceptibility of bloodstream infections among infants, children, and adolescents undergoing treatment for acute leukemia.
    PLoS One. 2026;21:e0358779.
    PubMed         Abstract available

  15. LLORET AVELLA M, Carmo M, Paladio Duran N, Blancher Parcerisa P, et al
    Economic and organizational impact of oral versus intravenous and subcutaneous administration of hypomethylating agents in patients with acute myeloid leukemia not eligible for intensive chemotherapy in Spain.
    PLoS One. 2026;21:e0358426.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum